Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributor.authorSeeman, Egoen
dc.contributor.authorVellas, Brunoen
dc.contributor.authorBenhamou, Claudeen
dc.contributor.authorAquino, Jean Pierreen
dc.contributor.authorSemler, Juttaen
dc.contributor.authorKaufman, Jean Marcen
dc.contributor.authorHoszowski, Krzysztofen
dc.contributor.authorVarela, Alfredo Rocesen
dc.contributor.authorFiore, Carmeloen
dc.contributor.authorBrixen, Kimen
dc.contributor.authorReginster, Jean Yvesen
dc.contributor.authorBoonen, Stevenen
dc.identifier.citationJournal of Bone and Mineral Research : the Official Journal of the American Society For Bone and Mineral Research; 21(7): 1113-20en
dc.description.abstractStrontium ranelate produces an early and sustained reduction of both vertebral and nonvertebral fractures in patients > or = 80 years of age.About 25-30% of the population burden of all fragility fractures in the community arise from women > or = 80 years of age, because this population is at high risk for all types of fracture, particularly nonvertebral fractures. Despite this, evidence that therapies reduce the risk of both vertebral and nonvertebral fractures in this group is lacking. The aim of this study was to determine whether strontium ranelate, an agent that reduces the risk of vertebral and nonvertebral fractures in postmenopausal women >50 years of age, also reduces fractures in the elderly.An analysis based on preplanned pooling of data from two international, phase III, randomized, placebo-controlled, double-blind studies (the Spinal Osteoporosis Therapeutic Intervention [SOTI] and TReatment Of Peripheral OSteoporosis [TROPOS]) included 1488 women between 80 and 100 years of age followed for 3 years. Yearly spinal X-rays were performed in 895 patients. Only radiographically confirmed nonvertebral fractures were included.Baseline characteristics did not differ in placebo and treatment arms. In the intent-to-treat analysis, the risk of vertebral, nonvertebral, and clinical (symptomatic vertebral and nonvertebral) fractures was reduced within 1 year by 59% (p = 0.002), 41% (p = 0.027), and 37% (p = 0.012), respectively. At the end of 3 years, vertebral, nonvertebral, and clinical fracture risks were reduced by 32% (p = 0.013), 31% (p = 0.011), and 22% (p = 0.040), respectively. The medication was well tolerated, and the safety profile was similar to that in younger patients.Treatment with strontium ranelate safely reduces the risk of vertebral and nonvertebral fractures in women with osteoporosis > or = 80 years of age. Even in the oldest old, it is not too late to reduce fracture risk.en
dc.subject.otherAge Factorsen
dc.subject.otherAged, 80 and overen
dc.subject.otherDouble-Blind Methoden
dc.subject.otherFractures, Bone.prevention & controlen
dc.subject.otherOrganometallic Compounds.administration & dosageen
dc.subject.otherOsteoporosis, Postmenopausal.complications.drug therapyen
dc.subject.otherRetrospective Studiesen
dc.subject.otherRisk Factorsen
dc.subject.otherSpinal Fractures.etiology.prevention & controlen
dc.subject.otherSpine.drug effectsen
dc.subject.otherThiophenes.administration & dosageen
dc.titleStrontium ranelate reduces the risk of vertebral and nonvertebral fractures in women eighty years of age and older.en
dc.typeJournal Articleen
dc.identifier.journaltitleJournal of Bone and Mineral Researchen
dc.identifier.affiliationAustin Hospital, University of Melbourne, Australiaen
Appears in Collections:Journal articles

Files in This Item:
There are no files associated with this item.

Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.